Find recruiting clinical trials for type 2 diabetes in the UK — from first-line metformin to cutting-edge GLP-1 and dual-agonist therapies. See where trials fit into your treatment pathway.
Free to use · Live data from ClinicalTrials.gov · Updated daily
See where clinical trials fit into your care journey
Initial treatment after diagnosis
Standard: Metformin + diet/exercise changes. Targets HbA1c below 48 mmol/mol
When metformin alone isn't enough
Standard: GLP-1 receptor agonists (semaglutide, dulaglutide) or SGLT2 inhibitors (dapagliflozin, empagliflozin)
Combining multiple drug classes for better control
Standard: Metformin + GLP-1 + SGLT2, or adding DPP-4 inhibitors, pioglitazone
When oral/injectable therapies can't maintain targets
Standard: Basal insulin, insulin intensification, tirzepatide (dual GIP/GLP-1), or newer agents
A condition where the body doesn't produce enough insulin or becomes resistant to it. Affects about 4.3 million people in the UK. Can cause heart disease, kidney damage, eye problems, and nerve damage if not well controlled.
The diabetes treatment landscape has transformed with GLP-1 agonists and dual agonists (tirzepatide). Trials are pushing further — triple agonists, oral semaglutide, islet cell regeneration, and treatments addressing cardiovascular and kidney complications alongside blood sugar.
Modern diabetes care focuses on more than blood sugar. SGLT2 inhibitors protect kidneys and hearts. Many trials now specifically test cardiovascular and renal outcomes, not just HbA1c reduction.
Loading trials from ClinicalTrials.gov...